Iambic Therapeutics raised $150 million in its IPO by selling 9.4 million shares at $16 each, and the AI-focused drug discovery biotech said proceeds will help advance IAM1363, its lead HER2 inhibitor now in a Phase I/Ib basket trial for HER2-altered solid tumors. Shares climbed more than 18% in their first day of trading Thursday as the company prepared to list on Nasdaq under the ticker IAM.

Why It Matters To Oncology

• Iambic is pitching an AI-enabled discovery engine to move multiple oncology assets forward, led by IAM1363 in HER2-altered solid tumors.

• Beyond HER2, its pipeline includes IAM217, a brain-penetrant allosteric KIF18A inhibitor for ovarian cancer, triple-negative breast cancer and other solid tumors, plus the CDK2/4 inhibitor IAM-C1.

• For clinicians watching drug discovery, the story is less about near-term efficacy data and more about whether AI-derived programs can translate into differentiated clinical candidates.

The Financials

• The company sold 9.4 million shares at $16 apiece, the midpoint of its previously disclosed range, raising $150 million.

• Iambic will trade on Nasdaq under the ticker IAM.

• Its stock rose more than 18% on its first day of trading, signaling strong early investor interest.

What They're Saying

• Iambic has framed the IPO proceeds as fuel for its internal cancer pipeline discovered through its “molecular superintelligence” platform.

• The public debut follows a newly announced alliance with AbbVie and adds to existing collaborations with Bayer, Jazz Pharmaceuticals, Lundbeck, Revolution Medicines and Takeda.

• The partner roster suggests external validation of the platform even as the key test remains clinical execution.

What's Next

• Near term, clinicians will be watching early safety, pharmacology and any preliminary activity signals from the Phase I/Ib basket study of IAM1363.

• Progression of IAM217 and IAM-C1 will show whether Iambic can build a broader oncology pipeline beyond its lead HER2 program.

• Longer term, the central question is whether the company’s AI-driven discovery approach can consistently produce oncology drugs that hold up in the clinic.